Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zolpidem-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that the product information of zolpidem-containing medicines used for short-term treatment of insomnia further highlight the risks of impaired driving

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE